Plerixafor+G-CSF-mobilized CD34+ cells represent an optimal graft source for thalassemia gene therapy

Blood

Volumn 126, Issue 5, 2015, Pages 616-619

  Karponi, Garyfalia ^a,b   Psatha, Nikoletta ^a   Lederer, Carsten Werner ^c   Adair, Jennifer Eileen ^d,e   Zervou, Fani ^a   Zogas, Nikolaos ^a   Kleanthous, Marina ^c   Tsatalas, Constantinos ^b   Anagnostopoulos, Achilles ^a   Sadelain, Michel ^f   Rivière, Isabelle ^f   Stamatoyannopoulos, George ^e   Yannaki, Evangelia ^a  

^a G PAPANICOLAOU HOSPITAL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^c CYPRUS INSTITUTE OF NEUROLOGY AND GENETICS   (Cyprus)

^d USA   (United States)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR; HEMOGLOBIN BETA CHAIN; PLERIXAFOR; CD34 ANTIGEN; HETEROCYCLIC COMPOUND;

ANIMAL EXPERIMENT; ARTICLE; BURST FORMING UNIT E; CD34 + T CELL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; EXPRESSION VECTOR; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; T LYMPHOCYTE; TELOMERE HOMEOSTASIS; THALASSEMIA; ANIMAL; AUTOTRANSPLANTATION; BETA-THALASSEMIA; GENE DOSAGE; GENE VECTOR; GENETICS; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; KNOCKOUT MOUSE; METABOLISM; PROCEDURES; STEM CELL MOBILIZATION; XENOGRAFT;

ANIMALS; ANTIGENS, CD34; BETA-GLOBINS; BETA-THALASSEMIA; GENE DOSAGE; GENE EXPRESSION; GENETIC THERAPY; GENETIC VECTORS; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HETEROGRAFTS; HUMANS; MICE; MICE, KNOCKOUT; TRANSPLANTATION, AUTOLOGOUS;

EID: 84940050411     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-03-629618     Document Type: Article

References (16)

1. Weatherall DJ, Clegg JB. The thalassemia syndrome. Oxford, UK: Blackwell Scientific Publishers; 1981.
2. Lucarelli G, Galimberti M, Polchi P, et al. Marrow transplantation in patients with thalassemia responsive to iron chelation therapy. N Engl J Med. 1993;329(12):840-844.
3. Lucarelli G, Isgrò A, Sodani P, Gaziev J. Hematopoietic stem cell transplantation in thalassemia and sickle cell anemia. Cold Spring Harb Perspect Med. 2012;2(5):a011825.
4. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica. 2004;89(10):1187-1193.
5. Sadelain M, Boulad F, Galanello R, et al. Therapeutic options for patients with severe beta-thalassemia: the need for globin gene therapy. Hum Gene Ther. 2007;18(1):1-9.
6. Yannaki E, Emery DW, Stamatoyannopoulos G. Gene therapy for β-thalassaemia: the continuing challenge. Expert Rev Mol Med. 2010;12:e31.
7. Champlin RE, Schmitz N, Horowitz MM, et al IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. Blood. 2000;95(12):3702-3709.
8. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175-181.
9. Yannaki E, Papayannopoulou T, Jonlin E, et al. Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjects. Mol Ther. 2012;20(1):230-238.
10. Yannaki E, Karponi G, Zervou F, et al. Hematopoietic stem cell mobilization for gene therapy: superior mobilization by the combination of granulocyte-colony stimulating factor plus plerixafor in patients with β-thalassemia major. Hum Gene Ther. 2013;24(10):852-860.
11. May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature. 2000;406(6791):82-86.
12. Boulad F, Wang X, Qu J, et al. Safe mobilization of CD34+ cells in adults with b-thalassemia and validation of effective globin gene transfer for clinical investigation. Blood. 2014;123(10):1483-1486.
13. th-3) mouse model. Hum Gene Ther Methods. 2014;25(6):317-327.
14. Larochelle A, Krouse A, Metzger M, et al. AMD3100 mobilizes hematopoietic stem cells with long-term repopulating capacity in nonhuman primates. Blood. 2006;107(9):3772-3778.
15. Genovese P, Schiroli G, Escobar G, et al. Targeted genome editing in human repopulating haematopoietic stem cells. Nature. 2014;510(7504):235-240.
16. Hu Z, Van Rooijen N, Yang Y-G. Macrophages prevent human red blood cell reconstitution in immunodeficient mice. Blood. 2011;118(22):5938-5946.